Given the paucity of patients at the RP2D, a larger expansion in pancreatic cancer at the appropriate dose would be necessary to address whether the combination of CXCR4 inhibitor with a PD-1/PD-L1 agent would be efficacious, particularly given the unconfirmed partial response noted in dose escalation. Here, CXCR4 is linked to pancreatic neoplasm.